Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has submitted a routine compliance certificate to NSE and BSE under Regulation 74(5) of SEBI's Depositories and Participants Regulations, 2018. The filing confirms that details of shares dematerialized and rematerialized during the quarter ended December 31, 2025, have been furnished to all stock exchanges where the company's shares are listed. Certificates from both CDSL and NSDL depositories, issued by the company's Registrar and Transfer Agent (KFin Technologies Limited) dated January 1, 2026, have been enclosed. This is a standard quarterly regulatory requirement with no financial or operational impact.
This is purely a procedural compliance filing with no impact on the company's financials, operations, or stock price. It simply confirms the company is meeting its routine quarterly disclosure obligations regarding share dematerialization activity.